Navigation Links
Key Protein May Lead to Faster Acting Anti-Depression Drugs
Date:3/23/2009

NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

This study, Role of p11 in Cellular and Behavior Effects of 5-HT4 Receptor Stimulation, solidifies the protein p11 as a key determinant of vulnerability to depression. This new research shows that p11 activates a serotonin receptor in the brain known for producing rapid antidepressant response.

"There is pressing clinical need for faster-acting antidepressants," says Greengard. "An understanding of the cellular mechanisms underlying the therapeutic actions of these drugs may lead to better treatments with fewer side effects." In fact, each year over 17 million American adults experience at least one episode of clinical depression. Depression experts claim that many people with a depressive illness never seek treatment. Perhaps if there were antidepressants available that could start working in hours or days rather than weeks or months, more people would seek treatment.

Previous research by Greengard, who was awarded the 2000 Nobel Prize in Medicine or Physiology, helped establish p11 as an important protein that regulates signaling in the brain by the neurotransmitter serotonin, which has long been linked to mood. Michael Stern Parkinson's Research Center scientists begun studying p11 because the serotonin system which is central to depression is connected to dopamine in Parkinson's disease.

The Michael Stern Parkinson's Research Foundation vision is a world without Parkinson's disease. To accomplish their vision, and cognizant that Parkinson's disease is the world's second most prevalent neurological disease after Alzheimer's, The Michael Stern Parkinson's Research Foundation mission is to fund promising, intensive, scientific and medical research that will delay Parkinson's onset, reduce the severity of its symptoms and provide better treatments, as well as fund research into related neurological diseases that can lead to a Parkinson's cure and, through education of health care professionals and the public, attempt to improve the quality of life of Parkinson's patients and their caregivers and families. www.ParkinsonInfo.org


'/>"/>
SOURCE The Michael Stern Parkinson's Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
2. Aiming at Multiple Alzheimers Proteins May be Key to Success
3. Protein Shown to Play a Key Role in Normal Development of Nervous System
4. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
5. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
6. Protein Key to Control Growth of Blood Cells
7. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
8. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
9. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
10. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
11. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... ... very strong with a total of 97 drug candidates. Pharma giant such ... involved in the development of the IPF therapeutics. The IPF pipeline comprised ... 15 are in Phase II stage, 12 are in Phase I stage, ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
(Date:3/23/2017)... Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” ... or whose acts have had a significant impact on the careers of all others involved. ... with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction took ...
(Date:3/23/2017)... , ... March 23, 2017 , ... March is National ... pack a punch when it comes to maintaining good health. Every day, two kidneys ... your kidneys filter every drop of your blood, eliminating waste, regulating fluid levels and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Hakim Unique Group ... technology company California Healthcom Group (CHG). , The HUG investment is a ... headquarters in California, CHG is a growing, internationally recognized healthcare management, technology, and ...
Breaking Medicine News(10 mins):